



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Roland Valdes Jr. et al.

Art Unit : 1648

Serial No.: 09/503,559

Examiner: U. Winkler

Filed

: February 11, 2000

Title

: DIHYDROOUABAIN-LIKE FACTOR AND DIAGNOSTIC & THERAPEUTIC

COMPOSITIONS AND METHODS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL

The following correspondence relating to this application is enclosed for filing:

- 1. Supplemental Information Disclosure Statement (1 page);
- 2. Form PTO-1449 (1 page);
- 3. Copies of Cited References (5 references);
- 4. Copy of Supplementary European Search Report (7 pages); and
- 5. A Return Postcard.

Please date stamp and return the enclosed postcard. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Ann S. Viksnins Reg. No. 37,748

Fish & Richardson P.C., P.A. 60 South Sixth Street, Suite 3300 Minneapolis, MN 55402 (612) 335-5070 telephone (612) 288-9696 facsimile

60227621.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

Signature

Lisa M. Becker

Typed or Printed Name of Person Signing Certificate



Attorney's Docket No.: 17541-005001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Roland Valdes Jr. et al.

Art Unit : 1648

Serial No.: 09/503,559

Examiner: U. Winkler

Filed

: February 11, 2000

Title

: DIHYDROOUABAIN-LIKE FACTOR AND DIAGNOSTIC & THERAPEUTIC

COMPOSITIONS AND METHODS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

This statement is being filed before the receipt of a first Office action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Ann S. Viksnins Reg. No. 37,748

Fish & Richardson P.C., P.A. 60 South Sixth Street

Suite 3300

Minneapolis, MN 55402 Telephone: (612) 335-5070 Facsimile: (612) 288-9696

60227610.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	July 6, 2004
Date of Deposit	Ma m
Signature	0

Lisa M. Becker Typed or Printed Name of Person Signing Certificate

Sheet	1	of	1
211000		V .	

Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 17541-005001

Application No. 09/503,559

Information Disclosure Statement
by Applicant
(Use several sheets if necessary)

Applicant Roland Valdes Jr. et al.

Filing Date

Group Art Unit 1648

(37, **Ö**FR §1.98(b))

February 11, 2000

=	U.S. Patent Documents							
	Examiner	Desig.	Document	Publication				Filing Date If Appropriate
	Initial	ID	Number	Date	Patentee	Class	Subclass	If Appropriate
		AA						
		AB						
		AC						
		AD						
		AE						
		AF						
		AG						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	lation No
	AH	GB 949 407	02/12/64	GB				
	AI							
	AJ							-
	AK							
	AL							_

	Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner	Desig.					
Initial	ID D	Document				
	AM	Qazzaz et al., "A commercially available standard for dihydroouabain has two chromatographically distinct biologically active components," Clinical Chemistry, 1997, 43:S191				
	AN	Qazzaz et al., "Simultaneous isolation of endogenous digoxin-like immunoreactive factor, ouabain-like factor, and deglycosylated congeners from mammalian tissues," <u>Archives of Biochemistry and Biophysics</u> , 1996, 328:193-200				
	AO	El-Masri et al., "An antiserum for detection of a newly discovered dihydroouabain-like factor (Dihydro-OLF) isolated from mammals," Clinical Chemistry, 1999, 45:A82				
	AP	Qazzaz et al., "A newly discovered lactone-hydrogenated isomer (Dihydro-OLF) of mammalian ouabain-like factor (OLF) differentially inhibits the sodium pump," FASEB J., 1999, 13:A1470				

Examiner Signature	-	Date Considered					
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							